Prevention of irradiation-induced salivary hypofunction by rapamycin in swine parotid glands

Zhao Zhu; Baoxing Pang; Ramiro Iglesias-Bartolome; Xiaoshan Wu; Lei Hu; Chunmei Zhang; Jinsong Wang; J. Silvio Gutkind; Songlin Wang

doi:10.18632/oncotarget.7941

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prevention of irradiation-induced salivary hypofunction by rapamycin in swine parotid glands

Zhao Zhu, Baoxing Pang, Ramiro Iglesias-Bartolome, Xiaoshan Wu, Lei Hu, Chunmei Zhang, Jinsong Wang, J. Silvio Gutkind and Songlin Wang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:20271-20281. https://doi.org/10.18632/oncotarget.7941

Metrics: PDF 1753 views | HTML 2297 views | ?

Abstract

Zhao Zhu1, Baoxing Pang1, Ramiro Iglesias-Bartolome2, Xiaoshan Wu1, Lei Hu1, Chunmei Zhang1, Jinsong Wang1, J. Silvio Gutkind3, Songlin Wang1

1Molecular Laboratory for Gene Therapy and Tooth Regeneration, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Capital Medical University School of Stomatology, Beijing 100050, China

2Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20852, USA

3Department of Pharmacology and Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA

Correspondence to:

Songlin Wang, e-mail: [email protected]

J. Silvio Gutkind, e-mail: [email protected]

Keywords: radiotherapy, salivary hypofunction, miniature pig, rapamycin, mTOR

Received: November 21, 2015 Accepted: February 09, 2016 Published: March 06, 2016

ABSTRACT

Radiotherapy is commonly used in patients with oral cavity and pharyngeal cancers, usually resulting in irreversible salivary hypofunction. Currently management of radiation damage to salivary glands still remains a great challenge. Recent studies show that activation of mammalian target of rapamycin (mTOR) occurs in salivary gland lesions, making it possible to apply mTOR inhibitor for treatment. Our results indicate inhibition of mTOR by rapamycin significantly alleviated irradiation-induced salivary hypofunction by restoring 46% salivary flow rate and protecting histological structures in swine. Furthermore, rapamycin protected human submandibular gland cell line (HSG) from irradiation-induced cell depletion and loss of cell proliferation capacity. These findings lay the foundation for a new clinical application of rapamycin to prevent irradiation-induced salivary hypofunction.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7941

Publication Alerts

Research Papers:

Prevention of irradiation-induced salivary hypofunction by rapamycin in swine parotid glands

Abstract